Anticoagulation Combined With Tocilizumab for Interleukin-6 Receptor Inhibition in Acute Cerebral Venous Thrombosis

This study aims to evaluate the efficacy and safety of tocilizumab, an interleukin-6 (IL-6) receptor antagonist, combined with standard anticoagulant therapy compared with standard anticoagulant therapy alone in patients with acute cerebral venous thrombosis (CVT).

Inclusion Criteria: 1. Aged 18-80 years. 2. Acute cerebral venous thrombosis (CVT) confirmed by neuroimaging, including MRI, MRV, CTV, MRBTI, or DSA. 3. Time from symptom onset to enrollment within 14 ± 14 days. 4. Written informed consent obtained from the participant. 5. Ability and willingness to comply with the study protocol and scheduled follow-up visits. Exclusion Criteria: 1. Treatment with immunosuppressive agents within 7 days before enrollment. 2. Isolated cortical vein thrombosis or isolated cavernous sinus thrombosis. 3. Concomitant immune-related diseases, including Behçet disease or systemic lupus erythematosus. 4. Concomitant infectious diseases. 5. Primary or secondary immunodeficiency. 6. Concomitant hematologic disorders or inherited coagulation abnormalities. 7. Intracerebral hemorrhage with extension into the ventricular system or subarachnoid space. 8. Imaging evidence of midline shift \>10 mm or cerebral herniation. Moderate or severe hepatic impairment, defined as Child-Pugh class B or C. 9. Creatinine clearance \